Antibodies, Viral; COVID-19 Vaccines; Cancer patients; Booster dose
Disciplines :
Immunology & infectious disease
Author, co-author :
Debie, Yana ; Université de Liège - ULiège > Fundamental and Applied Research for Animals and Health (FARAH) > FARAH: Santé publique vétérinaire ; Multidisciplinary Oncological Centre Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium, Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp and Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium
Vandamme, Timon; Multidisciplinary Oncological Centre Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium, Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp and Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium
Goossens, Maria E; SD Infectious Diseases in Humans, Observational Clinical Trials, Sciensano, Rue Juliette Wytsmanstraat 14, 1050 Brussels, Belgium
van Dam, Peter A; Multidisciplinary Oncological Centre Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium, Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp and Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium. Electronic address: peter.vandam@uza.be
Peeters, Marc; Multidisciplinary Oncological Centre Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium, Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp and Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium
Language :
English
Title :
Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer.
van Dam, P., Huizing, M., Roelant, E., Hotterbeekx, A., De Winter, F., Kumar-Singh, S., et al. Immunoglobin G/total antibody testing for SARS-CoV-2: a prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests. Eur J Cancer 148 (2021), 328–339.
Peeters, M., Verbruggen, L., Teuwen, L., Vanhoutte, G., Vande Kerckhove, S., Peeters, B., et al. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment. ESMO Open, 6(5), 2021, 100274.
Kamar, N., Abravanel, F., Marion, O., Couat, C., Izopet, J., Del Bello, A., Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med 385:7 (2021), 661–662.
Eliakim-Raz, N., Leibovici-Weisman, Y., Stemmer, A., Ness, A., Awwad, M., Ghantous, N., et al. Antibody titers before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged ≥60 years. JAMA 326:21 (2021), 2203–2204.
Gounant, V., Ferré, V.M., Soussi, G., Charpentier, C., Flament, H., Fidouh, N., et al. Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses. J Thorac Oncol: Off Publ Int Assoc Study Lung Canc, 2021, 1556-0864.
Shroff, R.T., Chalasani, P., Wei, R., Pennington, D., Quirk, G., Schoenle, M., et al. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. Nat Med 27:11 (2021), 2002–2011.
Rottenberg, Y., Grinshpun, A., Ben-Dov, I.Z., Oiknine Djian, E., Wolf, D.G., Kadouri, L., Assessment of response to a third dose of the SARS-CoV-2 BNT162b2 mRNA vaccine in patients with solid tumors undergoing active treatment. JAMA Oncol, 2021, 2021.6764.
Levin, E.G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med, 385(24), 2021, e84.
Ciabattini, A., Pastore, G., Fiorino, F., Polvere, J., Lucchesi, S., Pettine, E., et al. Evidence of SARS-CoV-2-specific memory B cells six months after vaccination with the BNT162b2 mRNA vaccine. Front Immunol, 12(3751), 2021.
Benucci, M., Damiani, A., Infantino, M., Manfredi, M., Grossi, V., Lari, B., et al. Presence of specific T cell response after SARS-CoV-2 vaccination in rheumatoid arthritis patients receiving rituximab. Immunol Res 69:4 (2021), 309–311.
